To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
As biotech deals slow, Catalio Capital amasses war chest
Valuations of public biotechnology companies have taken a hit, which is expected to depress valuations and dealmaking for privately held biotechs.
